This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.
Histologically confirmed metastatic or advanced GC/GEJC;
Received at least 2 cycles of anti-PD-1 or PD-L1 based therapy in the first-line setting;
Receiving at least 2 cycles of ICI-based second-line therapy;
ECOG PS 0 or 1;
patients had other malignancies within the past 5 years;
lack of survival and clinical efficacy data;
combined radiotherapy regimens in the second-line treatment.
All patients received combination therapy with ICIs inhibitors for at least 2 cycles in the first-line and at least 2 cycles of ICI inhibitor-based therapy in the second-line after first-line progression.
Cohort
Retrospective
ICIs(Immune checkpoint inhibitors)
Other interventionN
Progression-free survival (PFS)
Progression-free survival (PFS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first
overall survival (OS)
Progression-free survival (PFS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first
objective response rate (ORR)
The proportion of subjects with complete response (CR) and partial response (PR) in total subjects
disease control rate (DCR)
The proportion of subjects with complete response (CR) and partial response (PR) and stable disease (SD) in total subjects
safety
Adverse events (AEs) were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
Click on the lead sponsor to view all of their trials.
Yongxu Jia
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
